BioXcel Therapeutics (NASDAQ:BTAI) announced Thursday it would no longer provide commercial support for its FDA-approved ...

Research on using sedation to improve patient tolerance to noninvasive ventilation (NIV) after traumatic chest injuries is ...

Patients undergoing complex gastrointestinal malignancy surgeries experience various challenges such as immune system ...

The granted patent US11998529B2 outlines a method for treating agitation in human subjects using an oromucosal formulation of dexmedetomidine. The treatment protocol involves administering an initial ...

Reporting odds ratio (ROR), the proportional reporting ratio (PRR), and the Bayesian confidence propagation neural network (BCPNN) were employed to detect and assess adverse events associated with ...

gmail.com Objectives To investigate the safety and effectiveness of dexmedetomidine for sedating patients in whom previous attempts at sedation in the emergency department have failed. Methods A study ...

Dexmedetomidine hydrochloride 1 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Pain. According to GlobalData, Phase III drugs for Pain have a 54% phase ...

BACKGROUND: Dexmedetomidine is an α 2-receptor agonist used for sedation in the intensive care unit (ICU). Although dexmedetomidine is labeled for sedation in critically ill patients at doses up ...

Objectives: Although generally effective for sedation during noninvasive procedures, dexmedetomidine as the sole agent has not been uniformly successful for invasive procedures. To overcome some ...

Since traditional sedatives carry the risk of respiratory depression, this retrospective study was designed to compare sedation with the α 2 adrenergic agonist dexmedetomidine (DEX) and with GA for ...

Several meta-analyses have evaluated the antidelirium effects of dexmedetomidine in ICU patients, but their findings were inconsistent. Recently, several large multicentre randomised clinical trials ...